Bayer Schering Pharma was granted European marketing authorization for its new antihypertensive fixed dose combination drug PritorPlus® 80/25 and Kinzalkomb® 80/25 (80 mg telmisartan/25 mg hydrochlorothiazide) by the European Commission. The new formulation will be launched in Germany later this month, to be followed soon by selected

The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT® (valsartan and hydrochlorothiazide) and Exforge® (amlodipine and valsartan), as initial or ‘first-line’ therapies in patients likely to need multiple drugs to achieve their blood pressure goals.
The FDA approval of

The US Food and Drug
Administration (FDA) has approved two single-pill combination medications,
Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge(R)
(amlodipine and valsartan), as initial or ‘first-line’ therapies in
patients likely to need multiple drugs to achieve their blood pressure